Your Health, We Care
Regorafenib is the first small-molecule multi-targeted kinase inhibitor to be reported to prolong survival in patients with metastatic colorectal cancer who are resistant to standard therapy
Regorafenib is approved for third-line treatment in patients with metastatic colorectal cancer (mCRC), third-line treatment for patients with gastrointestinal stromal tumors (GIST) and second-line treatment for patients with hepatocellular carcinoma (HCC).
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
